Table 1 Baseline characteristics of the study population
Variable | n (%miss.) | Overall (n = 516) | No VTE (n = 501) | VTE (n = 15) | p* |
|---|---|---|---|---|---|
Age at diagnosis (years) | 516 (0.0%) | 65.1 [55.3–72.3] | 65.2 [55.2–72.4] | 62.1 [57.0–67.1] | 0.28 |
BMI (kg/m2) | 413 (20.0%) | 25.5 [23.0–28.7] | 25.4 [22.8–28.7] | 29.9 [25.6–36.6] | 0.005 |
Karnofsky Index at diagnosis (%) | 347 (32.8%) | / | / | / | 0.23 |
  ≤ 80% | / | 57 (16.4%) | 56 (16.6%) | 1 (11.1%) | / |
 90% | / | 116 (33.4%) | 115 (34.0%) | 1 (11.1%) | / |
 100% | / | 174 (50.1%) | 167 (49.4%) | 7 (77.8%) | / |
Family history of CRC | 256 (50.4%) | / | / | / | 0.76 |
 No family history | / | 217 (84.8%) | 211 (84.7%) | 6 (85.7%) | / |
 1st degree relative | / | 25 (9.8%) | 24 (9.6%) | 1 (14.3%) | / |
 2nd degree relative | / | 14 (5.5%) | 14 (5.6%) | 0 (0.0%) | / |
Smoker or Ex-Smoker | 358 (30.6%) | 121 (33.8%) | 117 (33.5%) | 4 (44.4%) | 0.49 |
Tumor localization | 514 (0.4%) | / | / | / | 0.84 |
 Cecum/Appendix | / | 56 (10.9%) | 56 (11.2%) | 0 (0.0%) | / |
 Ascending colon | / | 37 (7.2%) | 35 (7.0%) | 2 (13.3%) | / |
 Right flexure | / | 15 (2.9%) | 14 (2.8%) | 1 (6.7%) | / |
 Transverse colon | / | 19 (3.7%) | 18 (3.6%) | 1 (6.7%) | / |
 Left flexure | / | 22 (4.3%) | 21 (4.2%) | 1 (6.7%) | / |
 Descending colon | / | 9 (1.75%) | 9 (1.8%) | 0 (0.0%) | / |
 Sigma | / | 107 (20.8%) | 104 (20.8%) | 3 (20.0%) | / |
 Rectum | / | 246 (47.9%) | 239 (47.9%) | 7 (46.7%) | / |
  ≥ 2 localizations | / | 3 (0.6%) | 3 (0.6%) | 0 (0.0%) | / |
TNM | 509 (1.4%) | / | / | / | 0.75 |
 T1 | / | 9 (1.8%) | 9 (1.8%) | 0 (0.0%) | / |
 T2 | / | 27 (5.3%) | 27 (5.5%) | 0 (0.0%) | / |
 T3 | / | 372 (73.1%) | 360 (72.9%) | 12 (80.0%) | / |
 T4 | / | 101 (19.8%) | 98 (19.8%) | 3 (20.0%) | / |
TNM | 503 (2.5%) | / | / | / | 0.39 |
 N0 | / | 149 (29.6%) | 144 (29.5%) | 5 (33.3%) | / |
 N1 | / | 215 (42.7%) | 211 (43.2%) | 4 (26.7%) | / |
 N2 | / | 139 (27.6%) | 133 (27.3%) | 6 (40.0%) | / |
Stage | 512 (0.8%) | / | / | / | 0.81 |
 Stage II | / | 151 (29.5%) | 147 (29.6%) | 4 (26.7%) | / |
 Stage III | / | 361 (70.5%) | 350 (70.4%) | 11 (73.3%) | / |
Adjuvant chemotherapy | 516 (0.0%) | 339 (65.7%) | 329 (65.7%) | 10 (66.7%) | 0.94 |